CordenPharma Invests US$981 million (€900 mn) to Expand in USA & Europe
Introduction:
CordenPharma is investing US$981 million (€900 million) to expand its peptide platform at its sites in USA, and Europe.
Features:
The expansions, which encompass both enhancements to existing facilities and new constructions, are designed to meet the pharmaceutical industry's highest quality and technical standards for short and long peptide manufacturing, including BLA requirements.
The expansion of the Colourado, US site will focus on increasing large-scale peptide manufacturing capacity to meet the growing demand for GLP-1 peptides, driven by several long-term manufacturing contracts worth approximately €3 billion, with potential additional opportunities.
In Europe, CordenPharma will build a new greenfield site dedicated to small to large-scale peptide development and manufacturing, seamlessly integrated within its global facility network.
Once completed, these new constructions will be fully incorporated with world-class cGMP manufacturing facilities, supported by expert technical and regulatory teams. This integration will ensure that innovators supply chains are secured with comprehensive services ranging from APIs to drug products.
Specifications:
Name CordenPharma
Type Expansion
Budget US$900 million
